BRIEF published on 04/15/2025 at 10:05, 1 year 1 month ago IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials Immune Response IOmx Therapeutics IOMX-0675 Clinical Trial Approval Solid Tumor Therapy
BRIEF published on 04/15/2025 at 10:05, 1 year 1 month ago IOmx Therapeutics obtient l'approbation pour les essais cliniques sur IOMX-0675 Réponse Immunitaire IOmx Therapeutics IOMX-0675 Approbation Des Essais Cliniques Thérapie Des Tumeurs Solides
PRESS RELEASE published on 04/15/2025 at 10:00, 1 year 1 month ago iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675 iOmx Therapeutics receives regulatory approval for clinical trial application of IOMX-0675, a LILRB1/LILRB2 dual-targeting antibody, to reverse immune suppression in solid tumors Regulatory Approval Clinical Trial Application IOmx Therapeutics IOMX-0675 Solid Tumor
BRIEF published on 12/19/2024 at 14:05, 1 year 5 months ago IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
BRIEF published on 12/19/2024 at 14:05, 1 year 5 months ago IOmx Therapeutics fait progresser IOMX-0675 avec une application d'essai clinique Traitement Du Cancer Thérapeutique IOmx IOMX-0675 Demande D'essai Clinique Récepteurs Immunosuppresseurs
PRESS RELEASE published on 12/19/2024 at 14:00, 1 year 5 months ago iOmx Therapeutics submits Clinical Trial Application for IOMX-0675 iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF published on 08/22/2024 at 10:05, 1 year 9 months ago IOmx Therapeutics Initiates Phase Ib with OMX-0407 Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 08/22/2024 at 10:05, 1 year 9 months ago IOmx Therapeutics lance la phase Ib avec OMX-0407 Essai Clinique Thérapie Contre Le Cancer OMX-0407 Phase Ib Thérapeutique IOmx
PRESS RELEASE published on 08/22/2024 at 10:00, 1 year 9 months ago iOmx Therapeutics Initiates Phase Ib with OMX-0407 iOmx Therapeutics initiates Phase Ib clinical trial with OMX-0407, showing favorable safety profile and anti-tumor activity in solid tumors. Expansion phase opens in kidney cancer and angiosarcoma Solid Tumors Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 06/27/2024 at 10:05, 1 year 11 months ago IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer Chief Financial Officer Biopharmaceutical Leadership IOmx Therapeutics Florian Schmid
Published on 06/06/2026 at 04:45, 19 hours 52 minutes ago Battery X Metals Announces Closing of First Tranche of Private Placement to Advance Corporate Growth
Published on 06/06/2026 at 00:00, 1 day ago Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program
Published on 06/05/2026 at 17:00, 1 day 7 hours ago Silver Spruce Resources Inc. Provides an Update on the Jackie Project Acquisition
Published on 06/05/2026 at 15:00, 1 day 9 hours ago Norsemont Drills 20 Meters of 1.20 G/T Gold Equivalent at Bottom of Hole
Published on 06/05/2026 at 13:30, 1 day 11 hours ago CANEX Announces Gold Basin Resources Shareholders Approve Merger Arrangement With CANEX With 75.82% Support
Published on 06/06/2026 at 08:29, 16 hours 7 minutes ago Starting today, Trade Republic gives European retail investors direct access to IPOs
Published on 06/06/2026 at 00:20, 1 day ago Guild Wars 3, Modern Evolution of the MMORPG, Announced at Summer Game Fest for PC and PlayStation 5
Published on 06/05/2026 at 23:05, 1 day 1 hour ago Quantinuum Announces Closing of Upsized Initial Public Offering
Published on 06/05/2026 at 19:06, 1 day 5 hours ago EQS-Adhoc: Brockhaus Technologies AG: The Company's Management Board intends to return approx. €180 million of the proceeds from the sale of the Bikeleasing Group to shareholders
Published on 06/05/2026 at 18:48, 1 day 5 hours ago Digital transformation journey takes centre stage at ANGOTIC 2026
Published on 06/05/2026 at 19:00, 1 day 5 hours ago ALTAREA - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 06/05/2026 at 19:00, 1 day 5 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 06/05/2026 at 19:00, 1 day 5 hours ago ALTAREIT - Descriptif du programme de rachat d'actions autorisé par l'assemblée générale mixte du 4 juin 2026 et mis en œuvre par la Gérance
Published on 06/05/2026 at 19:00, 1 day 5 hours ago ALTAREA : Descriptif du programme de rachat d'actions autorisé par l'assemblée générale mixte du 4 juin 2026 et mis en œuvre par la Gérance
Published on 06/05/2026 at 19:00, 1 day 5 hours ago ALTAREIT - DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES MAI 2026
